Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii and Minocycline in H. pylori Infection
NCT07012785Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of saccharomyces boulardii in Helicobacter pylori infection, sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Helicobacter pylori eradication rate at 7 days. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07012785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012785.